Free Trial

Canaccord Genuity Group Reiterates Buy Rating for Allogene Therapeutics (NASDAQ:ALLO)

Allogene Therapeutics logo with Medical background
Remove Ads

Canaccord Genuity Group restated their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO - Free Report) in a research report released on Friday,Benzinga reports. They currently have a $14.00 price target on the stock.

ALLO has been the topic of several other research reports. William Blair reaffirmed an "outperform" rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. Citizens Jmp raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 target price on the stock in a research report on Friday. Finally, Piper Sandler cut their target price on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $9.40.

Check Out Our Latest Stock Report on ALLO

Allogene Therapeutics Stock Up 2.6 %

Shares of Allogene Therapeutics stock traded up $0.05 on Friday, hitting $1.94. 5,516,701 shares of the company were exchanged, compared to its average volume of 3,047,190. The stock has a market capitalization of $406.76 million, a price-to-earnings ratio of -1.24 and a beta of 1.02. The company has a 50-day moving average price of $1.94 and a 200 day moving average price of $2.31. Allogene Therapeutics has a 1-year low of $1.32 and a 1-year high of $4.74.

Remove Ads

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06. Research analysts forecast that Allogene Therapeutics will post -1.28 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Zachary Roberts sold 27,199 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the transaction, the executive vice president now owns 488,054 shares in the company, valued at approximately $868,736.12. The trade was a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of the business's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now owns 250,713 shares of the company's stock, valued at approximately $428,719.23. The trade was a 5.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 52,710 shares of company stock worth $92,125 over the last 90 days. Corporate insiders own 24.30% of the company's stock.

Hedge Funds Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ALLO. abrdn plc acquired a new position in Allogene Therapeutics in the fourth quarter valued at $776,000. Barclays PLC boosted its stake in Allogene Therapeutics by 101.5% in the third quarter. Barclays PLC now owns 342,973 shares of the company's stock valued at $959,000 after acquiring an additional 172,745 shares in the last quarter. Zacks Investment Management acquired a new position in Allogene Therapeutics in the third quarter valued at $1,446,000. Geode Capital Management LLC boosted its stake in Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company's stock valued at $9,037,000 after acquiring an additional 407,070 shares in the last quarter. Finally, Vontobel Holding Ltd. boosted its stake in Allogene Therapeutics by 788.4% in the fourth quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company's stock valued at $416,000 after acquiring an additional 173,457 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company's stock.

About Allogene Therapeutics

(Get Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

Read More

Analyst Recommendations for Allogene Therapeutics (NASDAQ:ALLO)

Should You Invest $1,000 in Allogene Therapeutics Right Now?

Before you consider Allogene Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.

While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads